Literature DB >> 2480164

Quantification of midodrine and its active metabolite in plasma using a high performance liquid chromatography column switching technique.

W Posch1, W Lindner.   

Abstract

An automated column-switching HPLC system is described for the simultaneous determination of midodrine, an alpha-adrenergic stimulating drug, and its active metabolite, ST-1059. Serum or plasma (850 microliters) is directly injected onto a RP18 (30 micrograms particle size) pre-column (9 x 4 mm ID) which acts as an on-line liquid-solid extractor and analyte enrichment system. The injection is followed by washing steps. The fraction containing the analytes is transferred onto an analytical RP18 column via step gradient elution where the final analysis is performed. Fluorescence detection is used (lambda ex 290 nm and lambda em 322 nm), and method detection limits of 0.8 ng/mL plasma were reached. These were sufficiently low to determine the plasma concentration-time profiles for both compounds following oral administration of 2.5 mg and 5 mg midodrine hydrochloride. The assay in serum or plasma was linear in the range of 1 to 15 ng analyte/mL, the recovery was greater than 95%, and the reproducibility was sufficient. The assay was rugged and was maintained by routinely changing the home-made, dry packed pre-column every 20th serum injection.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2480164     DOI: 10.1002/bmc.1130030403

Source DB:  PubMed          Journal:  Biomed Chromatogr        ISSN: 0269-3879            Impact factor:   1.902


  3 in total

1.  The in vitro metabolism of desglymidodrine, an active metabolite of prodrug midodrine by human liver microsomes.

Authors:  Masayuki Akimoto; Izumi Iida; Hiroki Itoga; Atsunori Miyata; Shizuko Kawahara; Yoshiro Kohno
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Jul-Sep       Impact factor: 2.441

2.  Electro-analytical sensing of anti-hypotensive agents: application to dosage forms and human urine.

Authors:  Sarah Alharthi; Hany A Batakoushy; Saif A Alharthy; Mahmoud O Abd El-Magied; Waheed M Salem
Journal:  Toxicol Res (Camb)       Date:  2022-02-07       Impact factor: 3.524

3.  Rationale for the prevention of syncope trial IV: assessment of midodrine.

Authors:  Satish R Raj; Peter D Faris; Maureen McRae; Robert S Sheldon
Journal:  Clin Auton Res       Date:  2012-05-19       Impact factor: 4.435

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.